The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shvarev E.G.

Astrakhan State Medical University

Dikareva L.V.

Astrakhan State Medical University

Zoeva A.R.

Astrakhan State Medical University

Tishkova O.G.

Astrakhan State Medical University

Zaitseva O.E.

Astrakhan State Medical University

Ukhanova Yu.Yu.

Astrakhan State Medical University

Hyperplastic processes in the endometrium: controversial and unresolved problems of the disease

Authors:

Shvarev E.G., Dikareva L.V., Zoeva A.R., Tishkova O.G., Zaitseva O.E., Ukhanova Yu.Yu.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2023;23(4): 35‑43

DOI: 10.17116/rosakush20232304135

Views: 1151

Downloaded: 31

Download PDF (RU)
Contact the author
Table of contents

HYPERPLASTIC PROCESSES IN THE ENDOMETRIUM: CONTROVERSIAL AND UNRESOLVED PROBLEMS OF THE DISEASE
HYPERPLASTIC PROCESSES IN THE ENDOMETRIUM: CONTROVERSIAL AND UNRESOLVED PROBLEMS OF THE DISEASE

To cite this article:

Shvarev EG, Dikareva LV, Zoeva AR, Tishkova OG, Zaitseva OE, Ukhanova YuYu. Hyperplastic processes in the endometrium: controversial and unresolved problems of the disease. Russian Bulletin of Obstetrician-Gynecologist. 2023;23(4):35‑43. (In Russ.)
https://doi.org/10.17116/rosakush20232304135

Подписка 2025-2 (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Stru­ctural and biochemical features of menstrual discharge in patients with uterine fibroids. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):85-90
Virus-associated progesterone-resistant chro­nic endo­metritis — the onco­risk situation?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):25-30

The incidence of hormone-dependent tumors of reproductive organs, including endometrial hyperplastic processes, has been steadily increasing over the past decades. The data on statistical indices of the disease, data on its etiology and pathogenesis, approaches to early detection, treatment and estimation of its efficiency are still disputable and controversial. Endometrial hyperplastic processes are not only among the most common gynecological diseases, but in some cases they are the background to the development of precancerous lesions and endometrial cancer. In the absence of clinically relevant tumour markers for screening, this makes the problem of endometrial cancer particularly important. The presented review is devoted not only to the statement and clarification of some controversial aspects of the abovementioned pathology, but also to the description of the optimal combination of noninvasive and minimally invasive techniques to obtain sufficient information about its state and different approaches to the estimation of the efficacy of the carried out treatment.

Keywords:

endometrial hyperplastic processes
morbidity statistics
pathogenetic features
evaluation of hormonal therapy

Authors:

Shvarev E.G.

Astrakhan State Medical University

Dikareva L.V.

Astrakhan State Medical University

Zoeva A.R.

Astrakhan State Medical University

Tishkova O.G.

Astrakhan State Medical University

Zaitseva O.E.

Astrakhan State Medical University

Ukhanova Yu.Yu.

Astrakhan State Medical University

Received:

17.05.2022

Accepted:

29.06.2022

List of references:

  1. Aksel EM, Vinogradova NN. Statistics of malignant neoplasms of the female reproductive organs. Onkoginekologiya. 2019;3:64-78. (In Russ). https://doi.org/10.52313/22278710_2018_3_64
  2. Dobrokhotova YuE, Saprykina LV. Giperplaziya endometriya. M.: GEOTAR-Media; 2016;90. (In Russ.).
  3. Nikitina IM, Horban NY, Mykytyn KV, Kondratiuk KO, Smiian SA, Kalashnyk NV, Gerevich NV. The state of reproductive health of women with hyperproliferative pathology of the endometrium. Review. Wiad Lek. 2021;74. 
  4. Sidorova IS, Unanyan AD, Vlasov PC, Evkina I, Karpov D. Hyperplastic processes of endometrium: the features of clinic and therapy. Vrach. 2011;3:40-42. (In Russ.).
  5. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, Wylie J, McMenamin UC. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020;28;15:4:e0232231. https://doi.org/10.1371/journal.pone.0232231
  6. Ozdegirmenci O, Kayikcioglu F, Bozkurt U, Akgul MA, Haberal A. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest. 2011;72:1:10-14.  https://doi.org/10.1159/000321390
  7. Strizhakov AN, Davydov AI, Pashkov VM, Lebedev VA. Benign diseases of the uterus. M.: GEOTAR-Media; 2014;312. (In Russ.).
  8. Santoro N, Crawford SL, El Khoudary SR, Allshouse AA, Burnett-Bowie SA, Finkelstein J, Derby C, Matthews K, Kravitz HM, Harlow SD, Greendale GA, Gold EB, Kazlauskaite R, McConnell D, Neal-Perry G, Pavlovic J, Randolph J, Weiss G, Chen H-Y, Lasley B. Menstrual cycle Hormone changes in women traversing menopause: study of women’s health across the nation. J Clin Endocrinol Metab. 2017;102:7:2218-2229. https://doi.org/10.1210/jc.2016-4017
  9. Chistyakova GN, Grishkina AA, Remizova II. Endometrial hyperplasia: classification, features of pathogenesis, diagnostics (literature review). Problemy reproduktsii. 2018;24:5:53-57. (In Russ.). https://doi.org/10.17116/repro20182405153
  10. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009;200:6:678.e1-6.  https://doi.org/10.1016/j.ajog.2009.02.032
  11. Bochkareva NV, Fomina SV, Kolomiets LA. Development of endometrial cancer in patients with different age groups with endometrial hyperplastic processes. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’. 2009;3:333-338. (In Russ.).
  12. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010;28:5:788-792.  https://doi.org/10.1200/JCO.2009.24.1315
  13. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, Glass AG, Richesson DA, Chatterjee N, Langholz B. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020;15:4:e0232231. https://doi.org/10.1186/s12905-021-01452-9
  14. Ikhena DE, Bulun SE. Literature review on the role of uterine fibroids in endometrial function. Reprod Sci. 2018;635-643.  https://doi.org/10.1177/1933719117725827
  15. Prilepskaya VN. Perimenopause and hormones. Problemy reproduktsii. Special’nyj vypusk. 2009;207-210. (In Russ.).
  16. Sabantsev MA, Shramko SV, Levchenko VG, Volkov OV, Tret’yakova TV. Endometrial hyperplasia without atypia and with atypia. Gynekologiya. 2021;23:1:18-24. (In Russ.). https://doi.org/10.26442/20795696.2021.1.200666
  17. Sugiyama Y, Gotoh O, Fukui N, Tanaka N, Hasumi K, Takazawa Y, Noda T, Mori S. Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma. Am J Pathol. 2020;190:1:234-251.  https://doi.org/10.1016/j.ajpath.2019.09.022
  18. Bokhman YaV. Guide to gynecological oncology. M.: Kniga po Trebovaniyu; 2012;464. (In Russ.).
  19. Gynecology by Emil Novak. Ed. by Berek J., Adashi I., Hillard P. M.: Praktika; 2002;267. (In Russ.).
  20. Conlon N, Paula A, Da C, Ashley CW, Segura S, De Brot L, Silva EM, Soslow RA, Weigelt B, DeLair DF. Endometrial carcinomas with a «Serous» Component in young women are enriched for DNA mismatch repair deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. Cancers. 2020;44:5:641-648.  https://doi.org/10.1097/pas.0000000000001461
  21. Unanyan AL, Sidorova IS, Kossovich YuM, Kogan EA, Demura TA. Chronic endometritis and HPV: disturbing news. The role of the combination of HPV infection and chronic endometritis in the pathogenesis of endometrial malignant tumors. Status Praesens. 2012;3:21-25. (In Russ.).
  22. Horban NY, Vovk IB, Lysiana TO, Ponomariova IH, Zhulkevych IV. Peculiarities of uterine cavity biocenosis in patients with different types of endometrial hyperproliferative pathology. J Med Life. 2019;12:3:266-270.  https://doi.org/10.25122/jml-2019-0074
  23. Kazachkova EA, Zatvornitskaya AV, Voropaeva EE, Kazachkov EL. Endometrial hyperplasia combined with chronic endometritis: clinicomorphological features. Ural’skii meditsinskii zhurnal. 2020;3:186:36-41. (In Russ.).
  24. Vereshchahina TV, Boychuk AV, Yakymchuk YB, Nikitina IM, Datsko TV. Morphological changes of the endometrium in hyperplastic process in women of reproductive age. Wiad Lek. 2021;74:3 cz 1:388-394. 
  25. Metlitskaya MA, Rogov YuI. Analysis of the incidence of papillomavirus infection in endometrial hyperplastic processes and adenocarcinomas. Meditsinskie novosti. 2012;12:78-79. (In Russ.).
  26. Orazov MR, Radzinskii VE, Volkova SV, Khamoshina MB, Mikhaleva LM, Abitova MZ, Shustova VB. Chronic endometritis in women with endometriosis-associated infertility. Ginekologiya. 2020;22:3:15-20. (In Russ.).
  27. Mlodzik N, Lukaszuk K, Sieg W, Jakiel G, Smolarczyk R. Endometrial microbiota — do they mean more than we have expected? Ginekol Pol. 2020;91:1:45-48.  https://doi.org/10.5603/GP.2020.0010
  28. Mal’tseva LI, Sharipova RI, Tsyplakov DE, Zhelezova ME. Morphofunctional state of the endometrium in women with bacterial-viral endometritis. Akusherstvo, ginekologiya. 2017;108:7:87-92. (In Russ.).
  29. Bishtavi AH, Gornykh OA, Gulieva VN, Chikovani NG, Gogoladze KhT, Kostin AYu, Ivanov AE, Chabrov AM, Solopova AG, Tabakman YuYu, Manukhin IB. On the pathogenesis of endometrial hyperplasia. Opukholi zhenskoi reproduktivnoi sistemy. 2012;3-4:108-111. (In Russ.).
  30. Tapil’skaya NI, Gzgzyan AM, Kogan IYu. The hidden causes of reproductive failure. Viral infections in the development of chronic endometritis. Status Praesens. Akusherstvo, ginekologiya, besplodnyi brak. 2019;4:59:118-124. (In Russ.).
  31. Unanyan AL, Sidorova IS, Kossovich YuM, Kogan EA, Demura TA. Chronic endometritis and HPV: disturbing news. The role of the combination of HPV-infection and chronic endometritis in the pathogenesis of endometrial malignant tumors. Status Praesens. 2012;3:21-25. (In Russ.).
  32. Clinical recommendations. Endometrial hyperplasia. Coding according to the International Statistical Classification of Diseases and Health-related problems: N 85.0, 85.1. The developer of the clinical recommendation is the Russian Society of Obstetricians and Gynecologists. 2021. (In Russ.).
  33. Ghoubara A, Sundar S, Ewies AAA. Endometrial pathology in recurrent postmenopausal bleeding: observational study of 385 women. Climacteric. 2018;21:4:391-396.  https://doi.org/10.1080/13697137.2018.1461825
  34. Kachalina TS, Motovilova TM, Borovkova LV, Grechkanev GO, Ponomareva IV, Puchkova TN, Martyantseva IV, Zamyslova VP, Zinov’eva OS, Chikalova KI., Sirotina L.Z. An integrative assessment of menstrual blood biomarkers in the diagnosis of non-neoplastic endometrial pathology. Akusherstvo i ginekologiya. 2019;3:121-126. (In Russ.). https://doi.org/10.18565/aig.2019.3.121-126
  35. Kuznetsova IV. Russian and international approaches to the management of patients with endometrial hyperplasia. Akusherstvo i ginekologiya. Portal CON-MED.RU. 2020. (In Russ.).
  36. Rotenberg O, Doulaveris G, Fridman D, Renz M, Kaplan J, Xie X, Goldberg GL, Dar P. Long-term outcome of postmenopausal women with proliferative endometrium on endometrial sampling. Am J Obstet Gynecol. 2020;223:6:896.e1-896.e7.  https://doi.org/10.1016/j.ajog.2020.06.045
  37. Dubrovina SO, Berlim YuD. Proliferation and angiogenesis markers of endometrial hyperplasia. Problemy reproduktsii. 2012;3:22-27. (In Russ.).
  38. Hanegem N, Prins MMC, Bongers MY, Opmeer BC, Sahota DS, Mol BWJ, Timmermans A. The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2016;197:147-155.  https://doi.org/10.1016/j.ejogrb.2015.12.008
  39. Iversen ML, Dueholm M. Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9—14 years. Eur J Obstet Gynecol Reprod Biol. 2018;222:171-175.  https://doi.org/10.1016/j.ejogrb.2018.01.026
  40. Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74:5:676-687.  https://doi.org/10.1111/his.13776
  41. Allison KH, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol. 2008;32:5:691-698.  https://doi.org/10.1097/PAS.0b013e318159a2a0
  42. Management of endometrial hyperplasia. 2016. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf
  43. Davydov AI, Novruzova NKh, Strizhakov AN. Endometrial hyperplasia: analysis of the WHO 2014 classification and the RCON & BSGE protocol from the standpoint of their own results. Voprosy ginekologii, akusherstva i perinatologii. 2018;17:4:11-24. (In Russ.).
  44. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol. 2000;76:3:287-290.  https://doi.org/10.1006/gyno.1999.5580
  45. Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75:2:135-136.  https://doi.org/10.1055/s-0034-1396256
  46. Zaino R, Carinelli SG, Ellenson LH, Eng C, Katabuchi H, Konishi I, Lax S, Matias-Guiu X, Mutter GL, Peters WAI, Sherman ME, Shih I-M, Soslow R and Stewart CJR. Tumours of the Uterine Corpus: Epithelial Tumours and Precursors. Lyon: WHO Press; 2014.
  47. Raffone A, Travaglino A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet. 2019;299:5:1233-1242. https://doi.org/10.1007/s00404-019-05103-1
  48. Makhina EV, Pichugina AK, Koldysheva EV, Molodykh OP, Lushnikova EL. Diagnostic and prognostic significance of evaluation of proliferative activity of endometrial cell populations in hyperplastic and neoplastic processes. Fundamental’nye issledovaniya. 2014;10:2:420-427. (In Russ.).
  49. Arutyunyan NA, Dzhibladze TA, Zuev VM, Ishchenko AI, Khokhlova ID, Berishvili MV. Immunohistochemical features of the endometrium in women of various age groups with infertility and hyperplastic processes in the endometrium. Rossiiskii vestnik akushera-ginekologa. 2015;15:3:15-19. (In Russ.). https://doi.org/10.17116/rosakush201515315-19
  50. Mitselou A, Ioachin E, Vougiouklakis T. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In Vivo. 2003;17:5:469-477. 
  51. Levakov SA, Sheshukova NA, Kedrova AG, Fedotova AS, Obukhova EA. Molecular biological profiles of endometrial hyperplasia and endometrial intraepithelial neoplasia. Opukholi zhenskoi reproduktivnoi sistemy. 2018;14:2:76-81. (In Russ.).
  52. Karapetyan OV, Fomochkina II, Zyablitskaya EYu, Kubyshkin VA, Kovalenko EP, Korobova PG, Makalish TP, Kubyshkin AV. The state of local markers of inflammation and apoptosis in the endometrium in hyperplasias of varying severity. Meditsinskii vestnik Severnogo Kavkaza. 2020;15;3:342-347. (In Russ.).
  53. Ukhanova YuYu, Dikareva LV, Shvarev EG, Ayupova AK. An integrated approach to the diagnosis of uterine fibroids and the assessment of the rate of its growth. Opukholi zhenskoi reproduktivnoi sistemy. 2015;11:4:71-75. (In Russ.).
  54. Gallos ID, Alazzam M, Clark TJ, Faraj R, Rosentha A, Smith PP, Gupta JK. Management of endometrial hyperplasia. Green-top Guideline No. 67. RCOG/BSGE Joint Guideline; 2016. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg67
  55. Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Chatterjee J Acta Oncol. 2019;58:3:342-352.  https://doi.org/10.1080/0284186x.2018.1540886
  56. Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Acta Obstet Gynecol Scand. 2019;98:9:1086-1099. https://doi.org/10.1111/aogs.13587
  57. Gabidullina RI, Smirnova GA, Nukhbala FR, Valeeva EV, Orlova YuI, Shakirov AA. Hyperplastic processes of the endometrium: modern tactics of patient management. Ginekologiya. 2019;21:6:53-58. (In Russ.). https://doi.org/10.26442/20795696.2019.6.190472
  58. Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update. 2015;21:748-761.  https://doi.org/10.1093/humupd/dmv038
  59. Posiseeva LV, Gerasimov AM, Petrova UL. Glycodelin in obstetric and gynecological practice: past, present, future. Problemy Reproduktsii. 2020;26:3:11-22. (In Russ.). https://doi.org/10.17116/repro20202603111
  60. So KH, Lee CL, Yeung WS, Lee K.F. Glycodelin suppresses endometrial cell migration and invasion but stimulates spheroid attachment. Reprod Biomed Online. 2012;24:6:639-645.  https://doi.org/10.1016/j.rbmo.2012.03.004
  61. Gao J, Mazella J, Seppala M, Tseng L. Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol Cell Endocrinol. 2001;176:1-2:97-102.  https://doi.org/10.1016/s0303-7207(01)00450-6
  62. Ohta K, Maruyama T, Uchida H, Ono M, Nagashima T, Arase T, Kajitani T, Oda H, Morita M, Yoshimura Y. Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth. Mol Hum Reprod. 2008;14:1:17-22.  https://doi.org/10.1093/molehr/gam081
  63. Volodin MA, Bokhman YaV, Shvarev EG, Kostina LA, Safronnikova NR, Shcherbakova LA, Maksimov SYa. Method for determining hormone sensitivity of endometrial cancer. The copyright certificate for the invention. 1988. (In Russ.).
  64. Polishchuk LZ, Shvarev EG, Volodin MA, Ganina KP. Morphofunctional assessment of hormone sensitivity of endometrial cancer in the treatment of progestogens. Methodical recommendations. Kiev. Republican Center for Scientific Medical Information. 1991. (In Russ.).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.